Helius Medical Technologies Inc. (NASDAQ: HSDT) has seen a decline in stock performance recently, with a -4.25% fall in stock price over the last five trading sessions. HSDT has a 36-month beta value of 1.23 and a public float of 27.89M, with short sellers holding 1.12% of that float. Analysts have varying opinions on the stock, with some recommending a “buy” while others recommend a “hold.” Insider trading activities indicate confidence in the company’s future growth potential. HSDT’s equity return is currently valued at -189.10, with asset returns at -138.00. The stock is trading significantly below its 50-day moving average and 52-week high.
Helius Medical Technologies Inc. (HSDT) Stock Performance and Analysts’ Predictions
Helius Medical Technologies Inc. (NASDAQ: HSDT) has seen a -4.25% fall in its stock price over the last five trading sessions, currently priced at $0.24. The company has a 36-month beta value of 1.23, and the public float for HSDT is 27.89M, with short sellers currently holding 1.12% of that float. On March 22, 2023, HSDT’s average trading volume was 671.98K.
Market Performance
HSDT has seen a -20.46% decline in its stock price over the last month and a -2.63% plunge over the past quarter, resulting in a -4.25% fall in stock performance for the week. The volatility ratio for the week is 10.47%, while the volatility levels for the past 30 days are at 12.60% for HSDT. The simple moving average for the last 20 days is -14.28%, with a simple moving average of -59.04% for the last 200 days.
Analysts’ Opinion of HSDT
Several brokerage firms have already released their reports for HSDT stocks. Noble Capital Markets listed HSDT as an “Outperform” and predicted a target price of $20 based on their research report published on March 24th, 2021.
HSDT Trading at -27.47% from the 50-Day Moving Average
After reaching its low price for the last 52 weeks, HSDT was unable to rebound, settling with a -94.05% loss for the given period. The stock is trading -18.32% lower than the 50-day moving average, which currently stands at $0.2646.
Over the last 5 trading sessions, HSDT fell by -8.25%, changing the moving average for the period of 200-days by -89.95% in comparison to the 20-day moving average. The company saw -25.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Several insider trading activities have been reported at HSDT, starting with President and CEO, Andreeff Dane, who purchased 80,041 shares at the price of $0.25 back on December 16. After this action, Dane now owns 332,517 shares of Helius Medical Technologies Inc., valued at $19,946 using the latest closing price. Additionally, Dane purchased 89,300 shares at $0.31 during a trade that took place back on November 23, holding 308,003 shares at $27,835 based on the most recent closing price.
Stock Fundamentals for HSDT
HSDT’s stock performance shows volatility in recent months, and the company has seen a decline in stock price over the past month and quarter. However, analysts at Noble Capital Markets predict a target price of $20 based on their research report from March 2021. The insider trading activities of Andreeff Dane are also noteworthy, indicating confidence in the company’s future growth potential.
Helius Medical Technologies Inc. (HSDT) Stock Performance Overview
Helius Medical Technologies Inc. (NASDAQ: HSDT) has seen a decline in equity return, currently valued at -189.10, with asset returns at -138.00. The stock is currently trading significantly below its 50-day moving average and 52-week high, indicating a bad performance recently. Analysts have varying opinions on the stock, with some recommending a “buy” while others recommend a “hold.”
Don’t miss interesting posts on Famousbio
